$2.50
-0.13-4.94%
At Close: -
$2.58
0.083.20%
After Hours: 7:52 PM EDT
15 minutes delayed
AN2 Therapeutics
ANTXNASDAQ
AN2 Therapeutics (NASDAQ:ANTX) Stock, Analyst Ratings, Price Targets, Forecasts
AN2 Therapeutics Inc has a consensus price target of $7.86 based on the ratings of 14 analysis. The 3 most-recent analyst ratings were released by Evercore ISI Group, JMP Securities, and Leerink Partners on May 16, 2024, April 2, 2024, and February 13, 2024, respectively. With an average price target of $5 between Evercore ISI Group, JMP Securities, and Leerink Partners, there's an implied 93.80% upside for AN2 Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
Evercore ISI Group
JMP Securities
Oppenheimer
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for AN2 Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/03/2024 | Buy Now | — | Leerink Partners | Joseph Schwartz | — | Upgrade | Market Perform → Outperform | Get Alert |
| 05/16/2024 | Buy Now | -22.48% | Evercore ISI Group | Liisa Bayko | $7 → $2 | Maintains | In-Line | Get Alert |
| 04/02/2024 | Buy Now | 132.56% | JMP Securities | Roy Buchanan | → $6 | Upgrade | Market Perform → Market Outperform | Get Alert |
| 04/01/2024 | Buy Now | — | Oppenheimer | Jeff Jones | — | Reiterates | Perform → Perform | Get Alert |
| 02/13/2024 | Buy Now | 171.32% | Leerink Partners | Joseph Schwartz | $23 → $7 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/12/2024 | Buy Now | 171.32% | Evercore ISI Group | Liisa Bayko | — | Downgrade | Outperform → In-Line | Get Alert |
| 02/12/2024 | Buy Now | — | Oppenheimer | Jeff Jones | — | Downgrade | Outperform → Perform | Get Alert |
| 02/12/2024 | Buy Now | — | JMP Securities | Roy Buchanan | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 01/04/2024 | Buy Now | 1062.79% | JMP Securities | Roy Buchanan | → $30 | Initiates | → Market Outperform | Get Alert |
| 03/30/2023 | Buy Now | 830.23% | Oppenheimer | Jeff Jones | $20 → $24 | Maintains | Outperform | Get Alert |
| 11/14/2022 | Buy Now | 868.99% | SVB Leerink | Joseph Schwartz | $27 → $25 | Maintains | Outperform | Get Alert |
| 04/19/2022 | Buy Now | 868.99% | Evercore ISI Group | Liisa Bayko | → $25 | Initiates | → Outperform | Get Alert |
| 04/19/2022 | Buy Now | 752.71% | Oppenheimer | Kevin DeGeeter | → $22 | Initiates | → Outperform | Get Alert |
| 04/19/2022 | Buy Now | — | Cowen & Co. | Ritu Baral | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for AN2 Therapeutics (ANTX) stock?
The latest price target for AN2 Therapeutics (NASDAQ:ANTX) was reported by Leerink Partners on July 3, 2024. The analyst firm set a price target for $0.00 expecting ANTX to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AN2 Therapeutics (ANTX)?
The latest analyst rating for AN2 Therapeutics (NASDAQ:ANTX) was provided by Leerink Partners, and AN2 Therapeutics upgraded their outperform rating.
When was the last upgrade for AN2 Therapeutics (ANTX)?
The last upgrade for AN2 Therapeutics Inc happened on July 3, 2024 when Leerink Partners raised their price target to N/A. Leerink Partners previously had a market perform for AN2 Therapeutics Inc.
When was the last downgrade for AN2 Therapeutics (ANTX)?
The last downgrade for AN2 Therapeutics Inc happened on February 13, 2024 when Leerink Partners changed their price target from $23 to $7 for AN2 Therapeutics Inc.
When is the next analyst rating going to be posted or updated for AN2 Therapeutics (ANTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AN2 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AN2 Therapeutics was filed on July 3, 2024 so you should expect the next rating to be made available sometime around July 3, 2025.
Is the Analyst Rating AN2 Therapeutics (ANTX) correct?
While ratings are subjective and will change, the latest AN2 Therapeutics (ANTX) rating was a upgraded with a price target of $0.00 to $0.00. The current price AN2 Therapeutics (ANTX) is trading at is $2.58, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.